Login to Your Account



$15M NOW; $225M POTENTIAL

Across barrier carrier? Armagen, Shire team in Hunter transcytosis

By Randy Osborne
Staff Writer

Wednesday, July 23, 2014
Angling to strengthen its position in Hunter syndrome by way of a method past the blood-brain barrier, Shire plc – already an investor in Armagen Technologies Inc. – paid $15 million up front and added an equity investment, sweetening the deal to develop the enzyme replacement therapy AGT-182 for somatic as well as CNS effects of Hunter syndrome.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription